Introduction
Coronary artery disease (CAD) leads to the death of more than seven million people each year worldwide [
1]. Guidelines for the treatment of CAD strongly encourage the use of optimal medical therapy as a first step in its management [
2,
3]. Percutaneous coronary intervention (PCI) is also frequently used in the management of CAD to relieve symptoms of angina. Registry data suggest that more than half of CAD patients have undergone a PCI, though this figure can vary depending on sex and geographical location [
4,
5].
Angina pectoris is a common symptom of CAD and affects around 112 million people globally [
6]. PCI has been shown to substantially reduce angina symptoms particularly in patients with severe angina [
7‐
9]. However, a randomized clinical study, COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; ClinicalTrials.gov #NCT00007657), showed that the benefits of PCI regarding quality of life (QoL) can be short term [
10] and that angina symptoms can persist in many patients after PCI [
11‐
13]. In a study including post-myocardial infarction (MI) patients, angina symptoms were reported to have occurred more frequently after 1 year in patients with a clinical history of PCI (25.2%) than in those without (15.4%) [
13]. COURAGE also showed that complementing optimal medical therapy with PCI does not lessen the risk of death, MI, or other major cardiovascular events in comparison to medical therapy alone, and may have no long-term or additional cardiovascular benefits [
14]. More recent meta-analyses of randomized trials comparing PCI and medical therapy in patients with CAD showed that PCI did not reduce the risk of mortality, non-fatal MI, or revascularization [
15,
16]. Two-year results from the FAME II (ClinicalTrials.gov #NCT01132495) trial showed a significant reduction in urgent revascularizations after fractional flow reserve-guided PCI plus medical therapy compared with medical therapy alone, but also with no significant effect on mortality or MI [
17]. These results may indicate a relevance of objective assessment of ischemia in patients with PCI to improve outcomes.
Optimal medical therapy is currently under-prescribed for symptomatic CAD patients and less than half benefit from such an approach prior to PCI [
18]. One such medical therapy, ivabradine, lowers heart rate by reducing the activity of the cardiac pacemaker through inhibition of the
I
f current, which in turn decreases cardiac workload and myocardial oxygen consumption [
19]. It is effective at reducing ischemia and symptoms of angina [
20‐
23]. The ADDITIONS (PrActical Daily efficacy anD safety of Procoralan
® In combinaTION with betablockerS; Controlled-Trials.com #ISRCTN53233058) trial [
24] showed that treating patients with stable angina with a combination of ivabradine and beta-blocker reduces heart rate, angina attacks, and nitrate consumption and improves Canadian Cardiovascular Society (CCS) classification along with QoL. Due to the fact that angina symptoms can persist in many patients after PCI, leading to significant impairment in QoL [
10‐
13], we aimed to evaluate ivabradine as an option for such patients with high resting heart rate. In this paper, we present a post hoc analysis of ADDITIONS that assesses the effect of ivabradine as part of a medical therapy when treating stable angina in patients with a clinical history of PCI at baseline.
Discussion
This analysis has shown that treating stable angina pectoris patients with a combination of ivabradine and beta-blockers lowered heart rate and reduced the frequency of angina symptoms to the extent that CCS classification and QoL improved independently of PCI status (
P < 0.0001 for all changes). Ivabradine was well tolerated by patients in both subgroups. These results are consistent with the findings of a pooled analysis of randomized trials assessing the effect of ivabradine in various subpopulations of angina pectoris patients including those with a previous PCI [
26].
PCI alleviates symptoms of angina by a local approach, as it directly removes defined, hemodynamically compromising lesions [
27]. It has an important role to play in the treatment of lifestyle-limiting angina [
28]. However, as our results indicate, angina symptoms can recur in a large proportion (51%) of post-PCI patients [
24]. In this study, 26% of the previous PCI group had received 2 or more stents and despite this they still suffered symptoms of angina. Recurrent symptoms were also reported in a study in a Swedish population where more than half of the women and a third of the men experienced angina symptoms 4 years after undergoing a PCI [
12]. This was also confirmed by findings from the COURAGE trial, where 41% of patients had angina 3 years after PCI treatment [
10].
As CAD is a diffuse disease process, frequently involving the entire coronary vasculature, it is more likely to benefit from systemic treatments such as medical therapy [
29]. This, combined with the fact that PCI does not lessen the risk of death or other cardiovascular outcomes in comparison with medical therapy alone [
14], suggests that optimal medical therapy for the treatment of stable angina should be pursued from the outset [
14,
18,
30] and is a course of action for symptom control currently recommended by the European and American guidelines for the treatment of CAD [
2,
3].
Heart rate is now believed to have a fundamental role in ischemia and angina. An elevated heart rate increases myocardial oxygen demand and reduces diastolic time, these effects can limit myocardial perfusion leading to ischemia and, in turn, triggering angina [
20,
31]. In patients with stable CAD, an elevated mean heart rate often precedes myocardial ischemia and is associated with a higher risk of cardiovascular events [
32‐
34]. Therefore, medical therapies that effectively reduce heart rate merit serious consideration, but are currently under-prescribed in the treatment of CAD and stable angina [
35].
Ivabradine reduces heart rate by specifically inhibiting the
I
f current, but does not affect blood pressure or other cardiac parameters. In reducing heart rate, ivabradine leads to a decrease in myocardial oxygen consumption and an increase in myocardial perfusion, thereby improving cardiac efficiency [
36]. Furthermore, ivabradine maintains the coronary vasodilation that occurs during exercise [
37]. The results of a placebo-controlled randomized study showed that ivabradine improves coronary collateral function in patients with stable CAD, which was accompanied by diminished ECG signs of ischemia [
38]. In contrast, beta-blockers—owing to their negative effect on myocardial contractility—prolong systole, reducing their beneficial effect on diastolic time. Beta-blockers may also affect vasomotion in the coronary circulation by unmasking alpha-adrenergic vasoconstriction resulting in constriction of large and small coronary arteries during exercise [
39]. Ivabradine has been shown to be an effective anti-anginal agent either as a stand-alone or as a combination therapy including beta-blockers [
21,
40]. Despite the fact that several guidelines recommend a target heart rate below 60 bpm in patients with angina [
2,
3], the CLARIFY (Controlled-Trials.com #ISRCTN43070564) registry revealed that only 22% of angina patients on beta-blockers achieved an optimal heart rate. Thus, many patients with still elevated heart rate could benefit from the addition of ivabradine to their treatment [
41].
In the ADDITIONS study, the addition of ivabradine led to a further substantial reduction in resting heart rate without excessive bradycardia. The effect was significant within the first 4 weeks of treatment despite prior and ongoing beta-blocker therapy. The effect of ivabradine was more pronounced in patients who had a baseline heart rate of ≥70 bpm. The relative reduction in the number of angina attacks and short-acting nitrate consumption was substantially larger in patients with a baseline heart rate of ≥70 bpm than <70 bpm at 1 month and 4 months. These data are in line with the pharmacological use-dependent properties of ivabradine, and therefore patients with a higher heart rate will benefit most from therapy with ivabradine [
42]. This is also in line with new recommendations from the European Medicines Agency (EMA) to initiate ivabradine therapy in patients with angina with a heart rate of ≥70 bpm.
QoL has been shown to be worse in patients with stable angina than in those without [
43]. In this post hoc analysis, treatment with ivabradine was associated with improved QoL in patients with stable angina. The CADENCE (Coronary Artery Disease in General Practice; ANZCTR.org.au #ACTRN12608000347369) study reported that 29% of stable angina patients experienced weekly angina (≥1 episode per week) and had a poorer QoL than patients who experienced angina less than once a week [
44]. These results correlate with our findings where the mean frequency of angina attacks dropped from >1 to <1 attack per week and patient QoL improved congruently. QoL is an important factor to be kept in mind when assessing the effectiveness of CAD treatment. The Society of Cardiovascular Angiography recommends that QoL be considered as an outcome in clinical trials and physicians care [
45]. While PCI improves patient QoL in the short term, it is often proportional to the severity of angina symptoms and there is less evidence supporting the benefits of PCI in the presence of severe comorbidities [
45]. The results of this post hoc analysis of ADDITIONS have demonstrated that combining ivabradine with beta-blocker in daily clinical practice reduces symptoms, improves CCS classification and also the QoL in patients with stable angina pectoris after PCI.
The recent data from the SIGNIFY (Study assessInG the morbidity–mortality beNefits of the I
f inhibitor ivabradine in patients with coronarY artery disease, Controlled-Trials.com #ISRCTN61576291) trial, conducted in patients with CAD on optimal medical treatment without clinical heart failure, did not demonstrate an effect of ivabradine on the incidence of the primary combined endpoint of cardiovascular death and non-fatal MI [
46]. In a pre-specified subgroup of symptomatic angina patients, there was a small, but statistically significant, increase in the incidence of the primary endpoint with no significant effects for the individual components of the primary endpoint. The incidence of bradycardia was the highest ever reported in any ivabradine trial (ivabradine, 18.0% vs. placebo, 2.3%;
P < 0.001). However, in the SIGNIFY trial a therapeutic regimen that is not approved for clinical use was applied, which included a higher initiation and uptitration dose (7.5 and 10 mg bid, respectively). The EMA conducted a review of ivabradine and made recommendations aimed at reducing the risk when using ivabradine in patients with angina. These recommendations included the importance of respecting the recommended dosage regimen—the starting dose should not exceed 5 mg, twice daily, and the maximum dose should not exceed 7.5 mg, twice daily. Furthermore, ivabradine should only be prescribed for patients with a resting heart rate of ≥70 bpm, with a contraindication for the concomitant use of ivabradine with diltiazem or verapamil [
47].
Regarding the safety profile of ivabradine in our study, only mild adverse drug reactions were reported in 0.6% of all patients. There were no reported cases of death, non-fatal MI or serious adverse drug reactions during the study.
A limitation of the study was its short duration (4 months) and that it was open label. There was also no placebo group to support the observed effect of treatment. Adherence to the treatment was not formally evaluated, though the significant reduction in heart rate observed throughout the study indicates good adherence. The frequency of weekly angina attacks and nitrate consumption was measured for only 1 week prior to the study visits. This was due, in part, to the non-interventional design of the study but also to avoid poor or inaccurate symptom recall by patients, which could occur over a longer period of time. Nevertheless, reporting/recall bias to some extent cannot be ruled out, but this may in part also be compensated using different measures of effectiveness (number of attacks, nitrate use, QoL). The missing placebo group, presence of possible reporting bias, and also relatively high resting heart rate at baseline in both patient groups (ivabradine effects are more pronounced with higher heart rate) can lead to an overestimation of the treatment benefit. On the other hand, ivabradine is often used in these high heart rates in practice, thus reflecting current clinical use of the compound. Only half of the patients were uptitrated to the recommended maximal dose (7.5 mg twice daily). Although it is not possible to say to which extent the symptomatic benefit may have increased in this study population by intensified uptitration, it has been demonstrated that heart rate lowering and anti-anginal effects of ivabradine are clearly dose dependent up to 7.5 mg twice daily [
20]. Another limitation of the study regarding specifically the sub-analysis of patients with PCI according to baseline heart rate (<70 bpm or ≥70 bpm) is the small number of patients with baseline heart rate <70 bpm (
n = 94). But it should be noted that ivabradine is not to be used in angina patients with baseline heart rate below 70 bpm according to recent EMA recommendations and European Union indication. Focus of this analysis is therefore clearly the patient cohort with heart rate ≥70 bpm. The main strength of this study was that it was undertaken in a large population of stable angina patients, who were already receiving optimized medical therapy, in over 800 centers in Germany. Moreover, the non-interventional study design supported an evaluation of treatment effects under conditions of routine clinical practice, taking into account patient subgroups that are usually excluded from clinical trials, such as elderly patients or patients with multiple comorbidities.
Acknowledgments
The study was supported by Servier Deutschland GmbH, Munich, Germany. Sponsorship and article processing charges for this study were funded by Servier Deutschland. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. The authors would like to thank all investigators for their contributions to the study. Subsets of these data were presented during poster sessions at the Autumn Congress of the German Society of Cardiology in 2013.